- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02476513
Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Patients with elevated central adiposity have an increased risk of esophageal disorders; we will correlate central adiposity with advanced esophageal pathologies (BE and EAC). This will be done by comparing body mass and fat distribution to tissue abnormalities found by pathology review of EGD biopsy. It is anticipated that the group of men in this study will have an increased likelihood of histopathologic alteration, which we will fit into our scale (0-no inflammation, 1-inflammation or BE, 2-BE with dysplasia, and 3-carcinoma) according to the referral pattern at UAB's outpatient gastroenterology clinic.
At the molecular level, there is also a relationship between pro-inflammatory cytokines and obesity, which may contribute to esophageal disorder [28]. Metabolically active fat cells secrete cytokines exclusive to adipose tissue (adipokines, leptin/adiponectin) as well as the more classic signaling molecules, tumor necrosis factor alpha (TNF-α); interleukins (IL)-1, IL-6, IL-8, and IL-10; monocyte chemoattractant protein 1 (MCP-1); and macrophage inflammatory protein 1 (MIP 1) [29-33]. Obesity-triggered pro-inflammatory molecules may promote tissue injury, leading to metaplasia and dysplasia in BE and, subsequently, to carcinoma.
Thus, by measuring these pro-inflammatory markers in our prospective patient population, it will be determined if patients with elevated levels exhibit pathologic disorders in the esophagus and if the differential expression of these molecular markers correlates with degree of esophageal disorder. We will analyze samples collected from men for adipocytokines and for inflammatory mediators that are released with tissue injury. Additionally, we will examine molecular markers that correlate with more advanced esophageal disorders (BE with high grade dysplasia and EAC).
Persistent stimulation is needed to cause stepwise progression from the early stages of esophageal injury, to BE, to carcinoma. Since the molecular events that lead to this transformation are not known, our goal is to profile biopsy tissues collected from the prospective cohort of 60 men, analyzed by IHC for p53, Ki67, cyclin D1, IL-6, IL-8, Cox-2, DKK-1, CD44, leptin, and adiponectin. These molecules are known to be involved in transformation of normal esophageal epithelium to EACs via progression from metaplasia and BE to low-grade dysplasia and high-grade dysplasia. [34]. The clinical outcome measurements will be correlated with the levels of these molecules, determined by IHC, with metaplasia, degree of dysplasia in BE, and stage of EAC. For BE tissues, there is a correlation between the extent of p53 staining and aggressive clinical features. Our preliminary findings on six BEs, selected from the patient population at UAB, indicate that a high proportion of p53 staining directly correlates with high-grade lesions
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- University of Alabama at Birmingham
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Men only who are referred for upper endoscopy for the first time.Or who have had normal upper endoscopy in the last 10 years
- Age criteria: 25-75 years in age
- Patients undergoing EGD and willing to also consent to tissue biopsy, blood work and CT scan.
- ECOG PFS 0-1
Exclusion Criteria:
- Unstable medical condition, such as uncontrolled diabetes mellitus or hypertension or active infections requiring systemic therapy
- Clinical evidence of cardiac or pulmonary dysfunction including, but not limited to, unstable congestive heart failure, uncontrolled arrhythmias, unstable coagulation disorders, or recent myocardial infarction (within 6 months)
- Documented history of erosive esophagitis or non-erosive esophageal luminal. No prior history of Barrett's esophagus.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Correlation of obesity and increase risk of esophageal adenocarcinomas
Periodo de tiempo: 1-2 years
|
We will use data collected from the waist measurements and the measurement compiled from the CT scan of the abdomen.
The correlate it with the actual tissue markers(if any) found from the pathologists review.
|
1-2 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Developing a group of tissue markers that specifically relates to a increase in esophageal cancer
Periodo de tiempo: 1-2 years
|
The pathologist and bio-marker laboratory will use the blood samples and tissue to provide a assay that can be used later to provide insight into the increase risk of developing Barrett's esophagus or esophageal adenocarcinoma
|
1-2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: James A Posey, M.D., University of Alabama at Birmingham
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- UAB 1354
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .